FindMyKOL
Clinical trialNCT00437957TerminatedPhase 1Interventional

Phase I Study of Temozolomide, Valproic Acid and Radiation Therapy in Patients With Brain Metastases

NCT00437957 is a phase 1 interventional trial sponsored by H. Lee Moffitt Cancer Center and Research Institute. As of 21 Nov 2026, it was terminated. It studies Temozolomide and Valproate in Brain Metastases. The registry lists an enrollment of 10 participants at 1 site in 1 country. The registry lists a start date of 31 Dec 2006 and a primary completion date of 30 Apr 2009. One of its registered investigators has a FindMyKOL profile.

SponsorH. Lee Moffitt Cancer Center and Research InstituteEnrollment10Brain Metastases
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00437957
FieldValue
Registry IDNCT00437957
StatusTerminated
PhasePhase 1
Study typeInterventional trial
Lead sponsorH. Lee Moffitt Cancer Center and Research Institute
Enrollment10
Registered sites1
Countries1
ConditionsBrain Metastases
DrugsTemozolomide and Valproate
Start31 Dec 2006
Primary completion30 Apr 2009
Study completion30 Apr 2009
Last update posted23 Feb 2017

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This type of study is called a "Phase I study". Its purpose is to determine the side effects of the two medicines listed in this study when given together with whole brain radiation, and the highest dose of valproic acid that can be given together with temozolomide and whole brain radiation. We will also study the drug combination's effectiveness in treating cancer. While both of these drugs and whole brain radiation have been used in people for many years, they have never been combined for the purpose of treating patients with cancer.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Florida, United States1 site
  • H. Lee Moffitt Cancer Center & Research Institute

    Tampa

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFlorida: 1 siteFL1District of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00437957

Each answer restates registry values shown on this page.

What is NCT00437957?

NCT00437957 is a phase 1 interventional trial sponsored by H. Lee Moffitt Cancer Center and Research Institute. It studies Temozolomide and Valproate in Brain Metastases.

Who leads NCT00437957?

The registry names Jade Homsi, MD (principal investigator, H. Lee Moffitt Cancer Center and Research Institute) and Sajeel Chowdhary, MD (principal investigator, H. Lee Moffitt Cancer Center and Research Institute) as overall officials.

Where does NCT00437957 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT00437957 study?

The registered drug and biological interventions are Temozolomide and Valproate.

When did NCT00437957 end?

The registry lists a primary completion date of 30 Apr 2009 and a study completion date of 30 Apr 2009. The sponsor last updated the record on 23 Feb 2017.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.